CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) (USD $)	6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (17,608,835)	$ (15,282,391)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	522,714	253,215
Amortization of intangible assets	2,735,996	1,285,145
Amortization of deferred consulting fees	18,993	32,559
Amortization of deferred license fees	54,750	54,750
Amortization of deferred rent	(10,080)	(4,446)
Amortization of deferred license, royalty and subscription revenues	(280)	(75,914)
Amortization of stock-based prepaid rent	42,293	0
Net loss allocable to non-controlling interest	(3,495,735)	(1,346,503)
Stock-based compensation	2,212,141	1,351,795
Deferred income tax benefit	(2,862,284)	0
Loss on sale or write-off of equipment	21,031	710
Write-off for uncollectible receivables	(16,356)	0
Changes in operating assets and liabilities:
Accounts receivable, net	(36,998)	(25,701)
Grant receivable	(132,876)	(269,365)
Inventory	(79,236)	(9,429)
Prepaid expenses and other current assets	(314,601)	(414,449)
Other long term assets	0	(5,000)
Accounts payable and accrued liabilities	(2,034,852)	(30,865)
Deferred revenues	35,352	62,381
Other long term liabilities	(186,386)	(41,731)
Net cash used in operating activities	(21,135,249)	(14,465,239)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(404,649)	(735,124)
Security deposit paid, net	(306,246)	(54,423)
Proceeds from the sale of equipment	4,000	0
Cash used in investing activities	(706,895)	(789,547)
CASH FLOWS FROM FINANCING ACTIVITIES:
Employee options exercised	12,500	0
Director options exercised	207,000	0
Proceeds from issuance of common stock	14,724,107	23,810,421
Fees paid on sale of common stock	(302,123)	(747,907)
Proceeds from sale of treasury stock and subsidiary warrants	13,582,209	1,819,500
Proceeds from sale of preferred stock	3,500,000	0
Proceeds from sale of common shares of subsidiary	468,000	255,502
Net cash provided by financing activities	32,191,693	25,137,516
Effect of exchange rate changes on cash and cash equivalents	(123,519)	73,599
NET CHANGE IN CASH AND CASH EQUIVALENTS:	10,226,030	9,956,329
CASH AND CASH EQUIVALENTS:
At beginning of the period	5,495,478	4,349,967
At end of the period	15,721,508	14,306,296
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	18,655	0
SUPPLEMENTAL SCHEDULE OF NON CASH FINANCING AND INVESTING ACTIVITIES:
Capital expenditure funded by capital lease borrowing	115,000	0
Common shares issued for consulting services	0	148,920
Common shares issued for rent	$ 0	$ 242,726